natgillin/translations-raw huggingface dataset:
In this comparative trial against an egg-derived influenza vaccine the seroprotection* rate, seroconversion or significant increase rate** and the geometric mean ratio (GMR) for anti-HA antibody (measured by HI) were assessed according to predefined criteria.
V tem primerjalnem preskušanju s cepivom, pridobljenim iz jajc, so bili stopnja serološke zaščite*, stopnja serološke konverzije ali pomembnega povečanja** in razmerje geometrične srednje vrednosti (GMR – Geometric Mean Ratio) za protitelesa proti HA (izmerjeno z inhibicijo hemaglutinina) ocenjeni glede na predhodno določene kriterije.
In this event, all antipsychotics, including lurasidone, should be discontinued.
V tem primeru je treba ukiniti zdravljenje z vsemi antipsihotiki, vključno z lurasidonom.
In this example, 12 units are loaded.
V tem primeru bo napolnjenih 12 enot.
In this group of patients, Bortezomib Accord is used in combination with dexamethasone, or with dexamethasone plus thalidomide.
Pri tej skupini bolnikov se zdravilo Bortezomib Accord uporablja v kombinaciji z deksametazonom ali pa z deksametazonom in talidomidom.
In this group of patients, Velcade is used in combination with dexamethasone, or with dexamethasone plus thalidomide; adults whose disease is getting worse after at least one other treatment and who have already had, or cannot undergo, a blood stem-cell transplant.
V tej skupini bolnikov se zdravilo Velcade uporablja v kombinaciji z deksametazonom ali pa z deksametazonom in talidomidom; odraslih, pri katerih se je bolezen poslabšala po vsaj enem drugem zdravljenju in katerim so že opravili presaditev krvnih matičnih celic ali pa presaditev pri njih ni mogoča.
In this latter group, the range and frequency of detection of quantifiable 9-cis-retinoic acid plasma concentrations in patients with KS after application of the medicinal product were comparable to the range and frequency of detection of quantifiable plasma concentrations of circulating, naturally-occurring 9-cis- retinoic acid in untreated individuals.
V zadnji sta bila obseg in pogostost odkritja merljive koncentracije 9-cis-retinoidne kisline v plazmi pri bolnikih s KS po dajanju zdravila primerljiva z obsegom in pogostostjo odkritja merljive koncentracije 9-cis-retinoidne kisline v plazmi, ki se naravno pojavlja pri nezdravljenih posameznikih.
In this leaflet
Kaj vsebuje navodilo
In this leaflet
Navodilo vsebuje
In this leaflet
Navodilo vsebuje:
In this leaflet the patient is addressed as ‘you’.
V tem navodilu bolnika naslavljamo kot "vi".
In this leaflet the shorter name CellCept is used.
V tem navodilu se uporablja skrajšano ime CellCept.
In this leaflet we call making the hole ‘piercing’.
V tem navodilu se za predrtje kapsule uporablja pojem „prediranje“.
In this leaflet:
Kaj vsebuje navodilo
In this leaflet:
Kaj vsebuje navodilo:
In this leaflet:
Navodilo vsebuje
In this leaflet…
Navodilo vsebuje
In this open label non- randomized single arm study, patients were treated with stavudine and lamivudine plus indinavir/ritonavir 400/100 mg every 12 hours.
V tej odprti nerandomizirani študiji z eno skupino so bolnike zdravili s stavudinom in lamivudinom v kombinaciji z indinavirjem/ritonavirjem 400/100 mg na vsakih 12 ur.
In this open-label extension study, clinical remission and clinical response were observed in patients for up to 124 weeks.
V tej odprti podaljšani študiji sta se klinična remisija in klinični odziv pri bolnikih ohranila do 124 tednov.
In this open-label extension study, the benefits of vedolizumab treatment as assessed by partial Mayo score, clinical remission, and clinical response were shown for up to 124 weeks.
V tej odprti podaljšani študiji, so se koristi zdravljenja z vedolizumabom, ovrednotene z delno oceno Mayo, s klinično remisijo in kliničnim odzivom ohranile do 124 tednov.
In this pack, you will find a device called an inhaler, together with capsules in blisters.
Pakiranje vsebuje inhalator skupaj s kapsulami v pretisnih omotih.
In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder.
V škatli boste našli inhalator in kapsule (v pretisnih omotih), ki vsebujejo zdravilo v obliki praška za inhaliranje.
In this pack, you will find an inhaler, together with capsules in blister.
Pakiranje vsebuje inhalator skupaj s kapsulami v pretisnih omotih.
In this pack, you will find an inhaler, together with capsules in blisters.
Pakiranje vsebuje inhalator skupaj s kapsulami v pretisnih omotih.
In this patient population, hypersensitivity reactions are particularly difficult to identify.
V tej populaciji bolnikov je preobčutljivostne reakcije še posebej težko prepoznati.
In this patient population, the most common adverse reactions (> 10%) with pembrolizumab were fatigue (24%), rash (19%), pruritus (18%), diarrhoea (12%), nausea (11%) and arthralgia (10%).
V tej populaciji bolnikov so bili najpogostejši neželeni učinki (> 10 %) zdravljenja s pembrolizumabom utrujenost (24 %), izpuščaj (19 %), pruritus (18 %), diareja (12 %), navzea (11 %) in artralgija (10 %).
In this pooled extended follow-up analysis, the median TTP was 60.1 weeks (95% CI: 44.3, 73.1) in patients treated with lenalidomide/dexamethasone (N = 353) versus 20.1 weeks (95% CI: 17.7, 20.3) in patients treated with placebo/dexamethasone (N = 351).
V tej zbrani podaljšani sledilni analizi je bila mediana TTP 60,1 tedna (95 % IZ: 44,3; 73,1) pri bolnikih, ki so prejemali lenalidomid/deksametazon (n = 353) v primerjavi z 20,1 tedna (95 % IZ: 17,7; 20,3) pri bolnikih, ki so prejemali placebo/deksametazon (n = 351).
In this population, including some children above 12 years, Repatha showed a consistent reduction in LDL-cholesterol levels beyond what can be achieved with existing fat-lowering medicines.
Pri tej populaciji, vključno z nekaterimi otroci, starejšimi od 12 let, so z zdravilom Repatha dosegli dosledno znižanje ravni holesterola LDL, ki je bilo boljše od znižanih vrednosti z obstoječimi zdravili za zniževanje ravni maščob.
In this population, Kaplan-Meier estimates of 1, 2 and 3 year survival were 92 %, 81 % and 74 %, respectively.
Pri tej populaciji je 1-, 2- in 3- letno preživetje, ocenjeno po metodi Kaplan-Meier, znašalo 92 %, 81 % in 74 %.
In this product, emodepside is responsible for the efficacy against Toxocara canis, Toxascaris leonina, Ancylostoma caninum, Uncinaria stenocephala and Trichuris vulpis.
Emodepsid v tem pripravku deluje na Toxocara canis, Toxascaris leonina, Ancylostoma caninum, Uncinaria stenocephala in Trihuris vulpis.
In this product, emodepside is responsible for the efficacy against Toxocara canis, Uncinaria stenocephala, Ancylostoma caninum and Trichuris vulpis.
Emodepsid v zdravilu deluje na Toxocara canis, Uncinaria stenocephala, Ancylostoma caninum in Trichuris vulpis.
In this product, emodepside is responsible for the efficacy against Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme and Aelurostrongylus abstrusus.
Emodepsid v tem pripravku deluje na Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme in Aelurostrongylus abstrusus.
In this product, the solubility of enzalutamide is increased by caprylocaproyl macrogolglycerides as emulsifier/surfactant.
V tem zdravilu je topnost enzalutamida povečana s pomočjo kaprilat kaprinat makrogolglicerolom kot emulgator/površinsko aktivno sredstvo.
In this protection experiment, the ferrets (six ferrets/group) were immunized intramuscularly with vaccine candidate containing four different doses of H5N1 antigen (3.75, 1.5, 0.6 and 0.24 µg of HA antigen) adjuvanted with half dose of AS03.
V tem preskusu zaščite so bele dihurje (šest belih dihurjev/skupino) intramuskularno cepili s kandidatnim cepivom, ki je vsebovalo štiri različne odmerke H5N1 antigena (3,75; 1,5; 0,6 in 0,24 µg HA antigena) s polovičnim odmerkom adjuvansa AS03.
In this protection experiment, the ferrets (six ferrets/group) were immunized intramuscularly with vaccine candidate containing three different doses of H5N1 antigen (7.5, 3.8 and 1.9 µg of HA antigen) adjuvanted with the standard dose or half dose of AS03.
V tem preskusu zaščite so bele dihurje (šest belih dihurjev/skupino) intramuskularno cepili s kandidatnim cepivom, ki je vsebovalo tri različne odmerke H5N1 antigena (7,5; 3,8 in 1,9 µg HA antigena) z adjuvansom, bodisi s standardnim bodisi s polovičnim odmerkom AS03.
In this second study, treatment failed in about 55% of patients receiving placebo compared with 39% receiving Humira.
V tej študiji zdravljenje ni bilo uspešno pri približno 55% bolnikov, ki so prejemali placebo, v primerjavi s 39% bolnikov, ki so prejemali zdravilo Humira.
In this section frequencies of adverse reactions are defined as follows: Very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1 000 to <1/100); rare (>1/10 000 to <1/1 000); very rare (<1/10 000), not known (frequency cannot be estimated from the available data).
V tem poglavju so pogostnostni neželenih učinkov določene, kot sledi: zelo pogosti (>1/10); pogosti (>1/100 do <1/10); občasni (>1/1 000 do <1/100); redki (>1/10 000 do <1/1 000); zelo redki (<1/10 000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
In this section frequencies of adverse reactions are defined as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000), not known (frequency cannot be estimated from the available data).
V tem poglavju so pogostnostni neželenih učinkov določene, kot sledi: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1 000 do <1/100); redki (≥1/10 000 do <1/1 000); zelo redki (<1/10 000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
In this section, the following categories of frequency have been used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
V tem poglavju so neželeni učinki navedeni po pogostnosti na naslednji način: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1000 do < 1/100), redki ( 1/10.000 do < 1/1000), zelo redki (< 1/10.000), neznano (ni mogoče oceniti iz razpoložljivih podatkov).
In this section, the following categories of frequency have been used: very common (1/10), common (1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
V tem poglavju so neželeni učinki navedeni po pogostnosti na naslednji način: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1000 do < 1/100), redki ( 1/10.000 do < 1/1000), zelo redki (< 1/10.000), neznano (ni mogoče oceniti iz razpoložljivih podatkov).
In this section, we call the injection kit the “kit”.
V tem poglavju bomo komplet za injiciranje imenovali samo "komplet".
In this set of patients, about one quarter were below or at most 6 months of age at diagnosis, and about one third approximately a quarter were between 7 and 36 months.
Pri tem nizu bolnikov jih je bila približno četrtina v času diagnoze mlajših od šest mesecev ali starih šest mesecev, približno tretjina pa od sedem do 36 mesecev.
In this situation Pradaxa and verapamil should be taken at the same time.
V tem primeru je treba jemati zdravilo Pradaxa in verapamil hkrati.
In this situation the patient must be ventilated.
Če se to zgodi, morate bolnika priključiti na umetno predihavanje.
In this situation, Inflectra should be re-initiated as a single dose followed by the maintenance dose recommendations described above.
V tem primeru bolniku najprej ponovno uvedite zdravilo Inflectra v enkratnem odmerku, pozneje pa mu spet predpišite vzdrževalni odmerek zdravila v skladu s priporočili, ki so podana zgoraj.
In this situation, Remsima should be re-initiated as a single dose followed by the maintenance dose recommendations described above.
V tem primeru bolniku najprej ponovno uvedite zdravilo Remsima v enkratnem odmerku, pozneje pa mu spet predpišite vzdrževalni odmerek zdravila v skladu s priporočili, ki so podana zgoraj.
In this situation, you may have received Simulect.
Možno je, da ste v takem primeru prejeli Simulect.
In this statistical analysis, patients who flared (and escaped to TCZ) during Part II or who withdrew, were classified as non-responders.
V tej statistični analizi so bolnike, ki se jim je v II. delu bolezen nenadno poslabšala (in so prejeli reševalno zdravljenje s tocilizumabom) ali so bili iz študije izključeni, šteli kot neodzivne.
In this study 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤ 35%) were treated with 3 infusions of infliximab 5 mg/kg, 10 mg/kg, or placebo over 6 weeks.
V tej študiji je bilo 150 bolnikov s srčnim popuščanjem stopnje III do IV po NYHA (iztisni delež levega ventrikla ≤ 35 %) zdravljenih s tremi infuzijami: infliksimab v odmerkih 5 mg/kg,10 mg/kg ali s placebom več kot 6 tednov.
In this study 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤ 35%) were treated with 3 infusions of Remicade 5 mg/kg, 10 mg/kg, or placebo over 6 weeks.
V tej študiji je bilo 150 bolnikov s srčnim popuščanjem stopnje III do IV po NYHA (iztisni delež levega ventrikla ≤ 35 %) zdravljenih s tremi infuzijami: zdraviloa Remicade v odmerkih 5 mg/kg,10 mg/kg ali s placebom več kot 6 tednov.
In this study 85% (64 out of 75) patients treated with RoActemra responded to treatment and no longer had fever after three months, compared with 24% (9 out of 37) patients receiving placebo.
Pri sistemskem juvenilnem idiopatskem artritisu se je 85 % (64 od 75) bolnikov , zdravljenih z zdravilom RoActemra, odzvalo na zdravljenje in po treh mesecih niso imeli več povišane temperature v primerjavi s 24 % (9 od 37) bolnikov, ki so prejemali placebo.
In this study a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Ivabradine Anpharm compared with placebo (3.4% vs 2.9% yearly incidence rates).
V tej študiji je pri posebni podskupini bolnikov s simptomatsko angino pektoris, zdravljenih z zdravilom Ivabradine Anpharm, prišlo do majhnega, vendar pomembnega zmanjšanja združenega tveganja smrti zaradi srčnožilne bolezni ali srčne kapi brez smrtnega izida v primerjavi s placebom (letni delež pogostnosti 3,4 % v primerjavi z 2,9 %).
In this study abacavir increased the mean methadone systemic clearance by 22%.
V tej študiji je abakavir pospešil povprečno izločanje metadona iz organizma za 22 %.
In this study Imbruvica was not compared with any other treatment.
V tej študiji ga niso primerjali z nobenim drugim zdravilom.
In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged ≥65 years compared with those less than 65 years (9.7% compared to 4.0%).
V tej študiji so pri bolnikih, ki so se zdravili s pioglitazonom in z insulinom, večji odstotek srčnega popuščanja opazili pri bolnikih, starih 65 let in starejših, v primerjavi z bolniki, mlajšimi od 65 let (9,7% v primerjavi s 4,0%).
In this study Mekinist was more effective than dacarbazine or paclitaxel in controlling the disease: patients taking Mekinist lived on average for 4.8 months without their disease getting worse, compared with 1.5 months for patients given dacarbazine or paclitaxel.
Študija je pokazala, da je bilo zdravilo Mekinist pri obvladovanju bolezni učinkovitejše od dakarbazina ali paklitaksela: stanje bolnikov, ki so jemali zdravilo Mekinist, se je povprečno poslabšalo po 4,8 meseca, medtem ko se je stanje bolnikov, ki so jemali dakabrazin ali paklitaksel, poslabšalo po 1,5 meseca.
In this study single oral doses of 200 mg nintedanib as well as multiple oral doses of 200 mg nintedanib administered twice daily for 15 days did not prolong the QTcF interval.
Dali so jim bodisi enkratne peroralne odmerke nintedaniba po 200 mg ali večkratne peroralne odmerke po 200 mg, dvakrat na dan 15 dni, ne da bi podaljšali interval QTcF.
In this study the age range of patients was 65-75 years, with 41% (183/447) of patients 70 years old or older.
V tej študiji je znašal starostni razpon bolnikov 65-75 let, z 41 % (183/447) bolnikov starih 70 let ali več.
In this study the frequency of hyponatraemia in the ranolazine group was rare.
V tej študiji je bila pogostnost hiponatriemije v skupini z ranolazinom redka.
In this study the objective response rate was 36.5% (95% CI: 24.7% - 49.6%) and the median time to progression (TTP) was 37.7 weeks (95% CI: 24.0 - 46.4 weeks).
V tej študiji je objektivni odziv na zdravljenje znašal 36,5 % (95 % IZ: 24,7-49,6 %) in mediani čas do napredovanja (TTP) 37,7 tedna (95 % IZ: 24,0-46,4 tedna).
In this study the ORR was 35.8% (95% CI: 26.8% – 47.5 %).
ORR v tej študiji je znašal 35,8 % (95 % IZ: 26,8-47,5 %).
In this study the safety profile in adolescent patients was similar to that in adults (see section 5.1).
V tej študiji je bil varnostni profil pri mladostnikih podoben varnostnemu profilu pri odraslih bolnikih (glejte poglavje 5.1).
In this study there was an increased incidence of hospitalisation due to CHF during the first 4–8 weeks of treatment with bosentan, which could have been the result of fluid retention.
V tej študiji je bilo število primerov hospitalizacije zaradi CHF v prvih 4–8 tednih zdravljenja z bosentanom povečano, kar je lahko bila posledica zadrževanja tekočine.
In this study, 14 patients with HES/CEL were treated with 100 mg to 1,000 mg of imatinib daily.
V tej študiji je 14 bolnikov s HES/CEL prejemalo od 100 mg do 1.000 mg matiniba na dan.
In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m² as a 1 hour intravenous infusion every weeks) and capecitabine (1250 mg/m² twice daily for 2 weeks followed by 1-week rest period).
V tem preskušanju so 255 bolnic randomizirali na zdravljenje z docetakselom (75 mg/m² v 1-urni intravenski infuziji na 3 tedne) in kapecitabinom (1.250 mg/m² dvakrat na dan 2 tedna s sledečim 1-tedenskim premorom).
In this study, 31% of patients achieved a haematological response (36% in previously untreated patients and 22% in previously treated patients) (Table 2).
V tej študiji je 31 % bolnikov doseglo hematološki odziv (36 % pri predhodno nezdravljenih bolnikih in 22 % pri predhodno zdravljenih bolnikih) (Preglednica 3).
In this study, 312 patients were randomized (2:1) to receive either 50 mg sunitinib or placebo, orally once daily on Schedule 4/2 until disease progression or withdrawal from the study for another reason (207 patients received sunitinib and 105 patients received placebo).
V tej študiji so312 bolnikov randomizirali (2:1) na peroralno uporabo 50 mg sunitiniba ali placeba enkrat na dan po shemi 4/2; bolnike so spremljali do napredovanja bolezni ali do umika iz študije zaradi kakšnega drugega razloga (sunitinib je prejemalo 207 bolnikov in placebo 105 bolnikov).
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO performance status 0 or 1, were randomized to one of two treatment arms.
V tej študiji so 358 bolnikov z inoperabilnim lokalno napredovalim SCCHN in stanjem zmogljivosti po WHO 0 ali 1 naključno razvrstili v enega od dveh terapevtskih krakov.
In this study, 5 patients were <2 years and 13 between 2 to
V tej študiji je bilo 5 bolnikov
In this study, 50% (51 out of 103) of patients taking Sovaldi and ribavirin for 12 weeks tested negative for hepatitis C, whereas 71 % (70 out of 98) of patients treated for 16 weeks tested negative.
Izidi preiskav za hepatitis C so bili v tej študiji negativni pri 50 % (51 od 103) bolnikov, ki so zdravilo Sovaldi in ribavirin jemali 12 tednov, in pri 71 % (70 od 98) bolnikov, ki so zdravili jemali 16 tednov.
In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two arms.
V tej študiji so 358 bolnikov z inoperabilnim lokalno napredovalim SCCHN in stanjem zmogljivosti po WHO 0 ali 1 randomizirali v enega od dveh terapevtskih krakov.
In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two arms.
V tej študiji so 501 bolnika z lokalno napredovalim SCCHN in stanjem zmogljivosti 0 ali 1 po WHO naključno razvrstili v enega od dveh krakov.
In this study, 87% of patients had disease that was IHC 3+, and 95% of patients entered had disease that was IHC 3+ and/or FISH positive.
V tej študiji je imelo 87 % bolnic bolezen, ki je bila IHK 3+, 95 % vključenih bolnic pa je imelo bolezen, ki je bila IHK 3+ in/ali FISH
In this study, 87% of patients had disease that was IHC 3+, and 95% of patients entered had disease that was IHC 3+ and/or FISH positive.
V tem preskušanju je imelo 87 % bolnic bolezen, ki je bila IHK 3+, 95 % vključenih bolnic pa je imelo bolezen, ki je bila IHK 3+ in/ali FISH-pozitivna.
In this study, 91% (296 out of 327) of patients tested negative for hepatitis C 12 weeks after the end of treatment.
V tej študiji so bili 12 tednov po končanem zdravljenju izidi preiskav za hepatitis C negativni pri 91 % (296 od 327) bolnikov.
In this study, a durable protection was statistically demonstrated to approximately 8 years.
V tej študiji je bilo trajanje zaščite statistično ocenjeno na približno 8 let.
In this study, ACR/EULAR remission (Boolean and Index) were also analysed as pre-specified exploratory endpoints, with higher responses observed in the tocilizumab groups.
V tej študiji so analizirali tudi remisijo glede na ACR/EULAR (na osnovi Boolean in Index definicije), ki sta bila vnaprej določena eksplorativna cilja – v skupinah s tocilizumabom so opazili večje odzive.
In this study, adding Empliciti to the two other medicines extended the average time before the disease got worse from 14.3 months to 18.5 months.
V tej študiji se je z dodatkom zdravila Empliciti k drugima zdraviloma čas do poslabšanja bolezni v povprečju podaljšal s 14,3 na 18,5 meseca.
In this study, all patients also received methotrexate and the main measure of effectiveness was the number of patients who achieved sustained remission (no detectable disease activity) after 52 weeks of treatment.
V tej študiji so vsi bolniki prejeli tudi metotreksat, glavno merilo učinkovitosti pa je bilo število bolnikov, ki so po 52. tednih zdravljenja dosegli trajno remisijo (ni bilo zaznanih znakov bolezni).
In this study, all, but one, patients engrafted, at a median of 15 (range, 10-23) days after allo-HCT.
V tej študiji je prišlo do prijetja presadka pri vseh bolnikih razen enega po 15 dneh (mediana) (razpon 10–23) po alo-HCT.
In this study, asymptomatic positive PCR only for CMV was reported in 77/147 (52.4%) of MabCampath-treated patients; symptomatic CMV infection was reported less commonly in 23/147 MabCampath treated patients (16%).
V tej študiji so poročali le o asimptomatsko pozitivnem PCR samo za CMV pri 77/147 (52,4 %) bolnikih, zdravljenimi z zdravilom MabCampath; simptomatska okužba s CMV je bila opažena manj pogosto pri 23/147 bolnikih, zdravljenimi z zdravilom MabCampath (16
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm.
V tej študiji so bili v kraku AT pogostejši kot v kraku AC: huda nevtropenija (90 % v prim. z 68,6 %), febrilna nevtropenija (33,3 % v prim. z 10 %), okužbe (8 % v prim. z 2,4 %), driska (7,5 % v prim. z 1,4 %), astenija (8,5 % v prim. z 2,4 %) in bolečine (2,8 % v prim. z 0 %).
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm.
V tej študijiso bili v kraku AT pogostejši kot v kraku AC: huda nevtropenija (90 % v prim. z 68,6 %), febrilna nevtropenija (33,3 % v prim. z 10 %), okužbe (8 % v prim. z 2,4 %), driska (7,5 % v prim. z 1,4 %), astenija (8,5 % v prim. z 2,4 %) in bolečine (2,8 % v prim. z 0 %).